Sotera Health Files 8-K on Financial Condition & Operations

TL;DR

**Sotera Health just dropped an 8-K on financial results, signaling an important update for investors.**

AI Summary

Sotera Health Company filed an 8-K on January 9, 2024, to report on its financial condition and operations, specifically under Item 2.02 and Item 7.01, which relate to Results of Operations and Financial Condition and Regulation FD Disclosure, respectively. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into the company's financial standing, potentially influencing stock valuation and investment decisions.

Why It Matters

This filing signals that Sotera Health is disclosing important financial updates, which can directly impact investor confidence and the company's stock price. Investors should review the full details to assess the company's performance.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the undisclosed financial details it references could contain either positive or negative news, creating uncertainty.

Analyst Insight

A smart investor would await the full details of the 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' referenced in this 8-K to make informed decisions, as this filing only announces the disclosure, not the specifics.

Key Numbers

• January 9, 2024 — Date of Report (The date the earliest event reported in the 8-K occurred and the filing date.)
• 001-39729 — Commission File Number (Unique identifier for Sotera Health Company's filings with the SEC.)

Key Players & Entities

• Sotera Health Company (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Sotera Health Company
• 9100 South Hills Blvd, Suite 300 Broadview Heights, Ohio 44147 (company) — business address of Sotera Health Company
• January 9, 2024 (date) — date of earliest event reported and filing date
• 001-39729 (dollar_amount) — Commission File Number
• 47-3531161 (dollar_amount) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.01 — ge on which registered Common stock, $0.01 par value per share SHC The Nasdaq Stoc

Filing Documents

• shc-20240109.htm (8-K) — 29KB
• january92024-ex991.htm (EX-99.1) — 17KB
• soterahealth_vxclrxrgbxreg.jpg (GRAPHIC) — 234KB
• 0001822479-24-000003.txt ( ) — 501KB
• shc-20240109.xsd (EX-101.SCH) — 2KB
• shc-20240109_lab.xml (EX-101.LAB) — 24KB
• shc-20240109_pre.xml (EX-101.PRE) — 13KB
• shc-20240109_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. See Item 7.01 - Updated Financial Guidance below, which is incorporated by reference herein.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Updated Financial Guidance On January 9, 2024, Sotera Health Company (the "Company") issued a press release announcing preliminary revenue results for full-year 2023 (the "Press Release"). A copy of the Press Release is attached hereto as Exhibit 99.1. These preliminary revenue results are based on information available to the Company as of January 9, 2024 and are subject to completion of the Company's year-end financial closing procedures and audit by the Company's independent registered public accounting firm. The range of revenues included in the Press Release is within the guidance provided at the time of the Company's third quarter earnings release. J.P. Morgan Healthcare Conference Presentation As previously announced, Michael B. Petras, Jr., Chairman and CEO of the Company, will deliver a business update at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 at 5:15 p.m. Eastern. A copy of the Company's slide presentation and a link to the live presentation, or a replay of the webcast of the presentation, may be accessed via the Investor Relations section of the Company's website. The information in Item 2.02 and Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly incorporated by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Sotera Health Company, dated January 9, 202 4

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sotera Health Company (Registrant) Date: January 9, 2024 By: /s/ Alexander Dimitrief Alexander Dimitrief Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR